Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FRAILOMIC

Financiado

Cerrado

Utility of omic based biomarkers in characterizing older individuals at risk for...

Utility of omic based biomarkers in characterizing older individuals at risk for frailty its progression to disability and general consequences to health and well being The FRAILOMIC Initiative The forecasted increase in the number of older people for this century will be accompanied by an increase of those with disabilities. Disability is usually preceded by a condition named frailty that encompasses changes associated... ver más

30/06/2018

SERMAS

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

SERVICIO MADRILENO DE SALUD No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 26 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-06-30 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

26 Participantes

SERMAS

0.00€ | Lider

International Committee of t...

N.D. | Participante

AOP

N.D. | Participante

MOSAIQUES DIAGNOSTICS GMBH

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BESTAGEING Biomarker Research Alliance for Diagnosing Heart Disease in... 15M€ Cerrado

BBDiag Blood Biomarker based Diagnostic Tools for Early Stage Alzhe... 3M€ Cerrado

CTQ2014-56777-R ESTRATEGIAS ANALITICAS DE IDENTIFICACION Y CARACTERIZACION D... 109K€ Cerrado

EMIF European Medical Information Framework 56M€ Cerrado

PDC2021-121350-I00 BIOMARCADORES PARA EL DIAGNOSTICO PRECOZ DEL DECLIVE COGNITI... 150K€ Cerrado

EMIF European Medical Information Framework 56M€ Cerrado

Líder del proyecto

SERVICIO MADRILENO DE SALUD No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 15M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The forecasted increase in the number of older people for this century will be accompanied by an increase of those with disabilities. Disability is usually preceded by a condition named frailty that encompasses changes associated with ageing, life styles and chronic diseases. To detect and intervene on it is of outstanding importance to prevent disability, as recovery from disability is unlikely. Recent documents stress the necessity of testing the clinical utility (in terms of risk prediction, diagnosis validity and prognostic significance) of the existing definition of frailty by using combinations of clinical criteria (current definition) and lab Biomarkers (BMs). We will measure the levels of blood and urine omic-based BMs in old people selected from eight cohorts, which include up to 75,000 participants, using standardized and innovative technology (WP1). This figure will allow us to test the research questions with a high power and validity. Combining these lab BMs with clinical BMs, we will develop predictive, diagnostic and prognostic models (WP2), with its modulation by nutrition and physical activity, in general old population and in old people showing some characteristics that confer a high risk for developing frailty (selected cardiovascular risk factors and diseases) (WP4). After that, a selected set of BMs will be validated prospectively (WP3) and assessed to find the best-fitted models (WP4). These models will guide the development of the ready-to-use kits to be implemented in the clinical settings. These kits will be at the center of dissemination and exploitation activities (WP5, WP6). A well-balanced consortium distributed over the individual tasks in the respective work packages will carry it out, with a strong participation of SMEs. In summary, FRAILOMIC is original, relevant, pertinent, feasible, overcome the usual research bottlenecks on Biomarkers, and fits perfectly with the topics addressed by the HEALTH.2012.2.1.1-2 call in human subjects

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores